Your browser doesn't support javascript.
SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study.
Meylan, Sylvain; Dafni, Urania; Lamoth, Frederic; Tsourti, Zoi; Lobritz, Michael A; Regina, Jean; Bressin, Philippe; Senn, Laurence; Grandbastien, Bruno; Andre, Cyril; Fenwick, Craig; D'Acremont, Valerie; Croxatto, Antony; Guilleret, Isabelle; Greub, Gilbert; Manuel, Oriol; Calandra, Thierry; Pantaleo, Giuseppe; Lazor-Blanchet, Catherine.
  • Meylan S; Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland sylvain.meylan@chuv.ch.
  • Dafni U; Laboratory of Biostatistics, School of Health Sciences, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece.
  • Lamoth F; Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Tsourti Z; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Lobritz MA; Laboratory of Biostatistics, School of Health Sciences, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece.
  • Regina J; Roche Biomedical, Basel, Switzerland.
  • Bressin P; Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Senn L; Occupational Health Service, Lausanne University Hospital, Lausanne, Switzerland.
  • Grandbastien B; Service of Hospital Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.
  • Andre C; Service of Hospital Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.
  • Fenwick C; Immunology Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • D'Acremont V; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Croxatto A; Department of Ambulatory Care and Community Medicine, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.
  • Guilleret I; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Greub G; Clinical Trial Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Manuel O; Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Calandra T; Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Pantaleo G; Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Lazor-Blanchet C; Immunology Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
BMJ Open ; 11(7): e049232, 2021 07 05.
Article in English | MEDLINE | ID: covidwho-1297975
ABSTRACT

OBJECTIVE:

To assess the SARS-CoV-2 transmission in healthcare workers (HCWs) using seroprevalence as a surrogate marker of infection in our tertiary care centre according to exposure.

DESIGN:

Seroprevalence cross-sectional study.

SETTING:

Single centre at the end of the first COVID-19 wave in Lausanne, Switzerland.

PARTICIPANTS:

1874 of 4074 responders randomly selected (46% response rate), stratified by work category among the 13 474 (13.9%) HCWs. MAIN OUTCOME

MEASURES:

Evaluation of SARS-CoV-2 serostatus paired with a questionnaire of SARS-CoV-2 acquisition risk factors internal and external to the workplace.

RESULTS:

The overall SARS-CoV-2 seroprevalence rate among HCWs was 10.0% (95% CI 8.7% to 11.5%). HCWs with daily patient contact did not experience increased rates of seropositivity relative to those without (10.3% vs 9.6%, respectively, p=0.64). HCWs with direct contact with patients with COVID-19 or working in COVID-19 units did not experience increased seropositivity rates relative to their counterparts (10.4% vs 9.8%, p=0.69 and 10.6% vs 9.9%, p=0.69, respectively). However, specific locations of contact with patients irrespective of COVID-19 status-in patient rooms or reception areas-did correlate with increased rates of seropositivity (11.9% vs 7.5%, p=0.019 and 14.3% vs 9.2%, p=0.025, respectively). In contrast, HCWs with a suspected or proven SARS-CoV-2-infected household contact had significantly higher seropositivity rates than those without such contacts (19.0% vs 8.7%, p<0.001 and 42.1% vs 9.4%, p<0.001, respectively). Finally, consistent use of a mask on public transportation correlated with decreased seroprevalence (5.3% for mask users vs 11.2% for intermittent or no mask use, p=0.030).

CONCLUSIONS:

The overall seroprevalence was 10% without significant differences in seroprevalence between HCWs exposed to patients with COVID-19 and HCWs not exposed. This suggests that, once fully in place, protective measures limited SARS-CoV-2 occupational acquisition within the hospital environment. SARS-CoV-2 seroconversion among HCWs was associated primarily with community risk factors, particularly household transmission.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: BMJ Open Year: 2021 Document Type: Article Affiliation country: Bmjopen-2021-049232

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: BMJ Open Year: 2021 Document Type: Article Affiliation country: Bmjopen-2021-049232